生物类似药切换后快速进展性肾小球肾炎一例
本文报道一例银屑病患者在从英夫利昔单抗原研药切换至生物类似药英夫利昔单抗-abda后数周内发生ANCA阴性寡免疫复合物新月体性肾小球肾炎的罕见病例。患者在原研药治疗下多年病情完全稳定,切换后出现快速进展性肾小球肾炎,无血清学异常,提示生物类似药在高级蛋白结构或糖基化方面的细微差异可能触发免疫耐受破坏。
要点
- 生物类似药切换后需警惕快速进展性肾小球肾炎等肾脏并发症。
- ANCA阴性寡免疫新月体肾炎可在无血清学异常时发生。
- 早期肾活检确认和及时免疫抑制治疗对肾功能恢复至关重要。
核心结论
- 生物类似药虽与参照药高度相似,但制造相关属性细微差异可能在易感个体中影响免疫原性并诱发肾小球肾炎。
研究设计与样本
- 单例病例报告,描述一例银屑病患者从英夫利昔单抗切换至英夫利昔单抗-abda后发生ANCA阴性寡免疫新月体性肾小球肾炎。
主要发现
- 患者在原研英夫利昔单抗治疗下多年病情完全稳定,切换至生物类似药后数周内出现快速进展性肾小球肾炎。
- 肾活检显示ANCA阴性寡免疫新月体性肾小球肾炎,且无血清学异常或新自身抗体形成。
临床怎么用
- 临床医生应对生物类似药切换后的肾脏并发症保持警惕,尤其是有自身免疫性疾病的患者。
- 对疑似病例应早期进行肾活检确认并及时启动免疫抑制治疗以优化肾功能恢复。
局限性
- 单例病例报告,不能确立因果关系,机制推测基于时间关联和缺乏其他解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapidly progressive glomerulonephritis is an uncommon but fulminant cause of acute kidney injury that requires urgent diagnosis and immunosuppression to prevent permanent kidney failure. We present a rare case of ANCA-negative pauci-immune crescentic glomerulonephritis occurring within weeks of transitioning from infliximab to the biosimilar infliximab-abda in a patient who had maintained years of complete stability on originator therapy, used for psoriasis. Although tumor necrosis factor-α inhibitors have been associated with paradoxical autoimmune phenomena, reported renal complications typically involve immune-complex glomerulonephritis, lupus-like nephritis, or ANCA-associated vasculitis, often accompanied by new autoantibody formation. The absence of serologic abnormalities, combined with the abrupt onset following biosimilar substitution, suggests a unique tolerance-breaking mechanism potentially driven by differences between biosimilars in higher-order protein structure or glycosylation. This case underscores the importance of recognizing that biosimilars, while highly similar to their reference products, may differ subtly in manufacturing-dependent attributes that influence immunogenicity in susceptible individuals. Clinicians should maintain vigilance for renal complications following biosimilar switches, particularly in patients with underlying autoimmune disease. Early biopsy confirmation and prompt initiation of immunosuppression remain essential to optimize renal recovery.
引用
- Bowers W, Garcia E, Wood N, et al. A Case of Bio-Dissimilarity: Rapidly Progressive Glomerulonephritis Following Switch From Infliximab to Infliximab-abda. Am J Kidney Dis. 2026. PMID: 42966592. doi:10.1053/j.ajkd.2026.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。